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ABSTRACT
INTRODUCTION: Traumatic brain injury (TBI) is a major public health problem,
causing approximately 52,000 deaths from 1.7 million injuries in the United States
annually, with a combined direct and indirect economic cost estimated at $60-75 billion
per year. Traumatic subarachnoid hemorrhage (tSAH), a subtype of closed head injury,
has a high prevalence within TBI—evident in up to two-thirds of moderately and
severely brain injured patients. tSAH is also associated with poor clinical outcomes;
some research suggests mortality and unfavorable outcome rates are two-to-three times
higher in patients with tSAH, based on brain imaging, compared to those without. To
date, no pharmacological treatment has been conclusively shown to improve outcomes in
humans for either moderate or severe TBI or for specific tSAH injury. The aim of this
study was to assess whether the effect of PROG was substantially different in study TBI
patients with evidence of tSAH on initial brain imaging compared to those that did not
have evidence of tSAH.
METHODS: ProTECT III clinical trial data was used for an exploratory, post hoc
subgroup analysis to determine the effect of the hormone progesterone (PROG) on
outcome. Study subjects with any abnormality on baseline brain imaging were included
in the analysis and two subgroups, tSAH positive (+tSAH) and tSAH negative (–tSAH),
were selected. The primary outcome evaluated was a favorable/unfavorable dichotomy
derived from the 6-months post-injury Extended Glasgow Outcome Scale (GOSE)
assessment, which evaluates both mortality and functional outcomes. Risk ratios (RRs)
were calculated for the total sample and each of the two subgroups and used as statistical
evidence for interaction between PROG and tSAH.
RESULTS: All subjects from the original ProTECT III trial cohort (N=882) with no
abnormalities found on baseline computed tomography (CT) image (n=125) or missing
image (n=1) were excluded from this analysis. Subjects with one or more abnormalities
noted on CT (+CT, n=756) were then divided into subgroups based on presence (n=582)
or absence (n=174) of tSAH. Subjects with +tSAH were more severely injured than
–tSAH (mean Rotterdam CT score 3.3 vs. 2.2; 3.1 overall) and had a lesser proportion of
favorable outcomes (47.4% vs. 74.3%; 53.6% overall). Compared to placebo, patients
treated with progesterone had marginally better likelihood of favorable outcomes (risk
ratio among +tSAH 1.06, 95% confidence interval [CI], 0.89 to 1.26; and RR among
–tSAH 1.02, 95% CI 0.85 to 1.22). A multivariable model, adjusted for baseline
differences in treatment group covariates did not yield substantially different results for
the effect of progesterone on favorable outcomes (+tSAH 1.07; 95% confidence interval
[CI], 0.84 to 1.36, –tSAH 1.08; 95% CI 0.75 to 1.56, +CT 1.06; 95% CI 0.87 to 1.29).
CONCLUSION: Our study demonstrated that progesterone did not result in different
effects in patients with or without tSAH than those without based on initial brain
imaging. This investigation supports previous research findings; tSAH is correlated with
more severe injury and worsened outcomes. Concomitant injuries found in +tSAH group
are likely worsening the outcomes over –tSAH, but this was not evaluated here. More
complex statistical modeling should be used on this data to determine if it provides
evidence that tSAH is an independent prognosticator of unfavorable outcome or merely
associated with more severely injured patients.	
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I. INTRODUCTION
Traumatic brain injury (TBI) is defined as “an alteration in brain function, or other
evidence of brain pathology, caused by an external force” (Menon, Schwab, Wright, &
Maas, 2010, p. 1637). TBIs can range from minor (such as a mild concussion) to
catastrophic and sometimes fatal injuries. As the magnitude of the brain injury increases,
so does the cost of treatment and amount of future disability associated with the injury.
Recent evidence shows staggering figures regarding the incidence and prevalence of
TBI; each year, just in the United States, millions of individuals are affected by brain
injury with billions of dollars of economic impact (Langlois, Rutland-Brown, & Wald,
2006).
In addition to the substantial cost of treatment and lost productivity, the burden of
injury of TBI is massive. The most severe nonfatal cases cause permanent and profound
morbidity, not only devastating the lives of the patients, but also those around them. The
disruption suffered by the families and loved ones of these patients and the emotional
impact of TBI will likely remain extremely difficult to quantify (Humphreys, Wood,
Phillips, & Macey, 2013, p. 282). To further complicate their situation and prognosis,
TBI patients are frequently at higher risk for a host of other harmful conditions, from
depression and substance abuse to epilepsy and Alzheimer’s disease (Langlois et al.,
2006, p. 376).
Decades of research have been performed with the hope of alleviating some of this
burden by improving diagnosis, clinical care, rehabilitation, and, consequently, the
outcomes and quality of life attained by these patients. Although significant advances
have been made in treatments throughout the course of the disease, from before the
injury occurs to rehabilitation and care years later, much work remains to be done in
virtually every area and at every stage of the trauma. Prevention and reduction of injury
by safety devices (such as seat belts and helmets), behaviors (like geriatric fall risk
assessments), and regulation (e.g. traffic safety measures) have undoubtedly saved
countless lives and lessened the extent of many of the injuries suffered. No treatment
will ever rival the avoidance of injury for the millions of TBIs sustained every year, so
continued efforts in these endeavors is clearly warranted.
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Clinical care has been greatly elevated as brain injury has become better
understood. Diagnoses are made more rapidly with fast, high-resolution brain imaging
technologies and refined, evidence-based clinical assessments. Advanced neurosurgical
procedures and sophisticated monitoring devices are pushing our capabilities to new
levels. Standardizing recommendations through the establishment of “best practice”
guidelines has improved the quality and consistency of care (Carpenter et al., 2015).
Specialized post-acute-phase facilities, such as Atlanta’s Shepherd Center, have
revolutionized not only the efficacy of the rehabilitation delivered to patients but have
shifted our fundamental expectations for the extent of recovery that is possible after a
TBI has been sustained (Kunik, Flowers, & Kazanjian, 2006).
Perhaps the area within TBI treatment that has the most potential for a significant
breakthrough is the pharmacological treatment of brain injury. The acute-phase care of
patients with moderate and severe brain injury is largely focused on supporting vital
physiologic processes during the complex biochemical changes that occur within the
brain and body as a result of TBI. Intervening in these injury cascades, repairing
damage, or preventing further harm is the elusive “Holy Grail” of treatment for the more
severely brain-injured patient. Neurosurgical procedures are indicated and effective in
certain types of TBI, and physiologic mechanisms and measurements such as blood
pressure or serum lab values can be manipulated through pharmacologic agents. But the
search for medications that act directly on the injury and sequelae to improve the
outcome of TBI patients has been a long, expensive, and unsuccessful one. Hundreds of
millions of dollars have been spent and thousands of subjects enrolled in clinical trials
without a single proven-effective pharmacological intervention that specifically treats
acute traumatic brain injury (National Institutes of Health, 2015; Narayan et al., 2002).
The purpose of the present investigation is to evaluate the effect of the hormone
progesterone in a specific subtype of TBI, called traumatic subarachnoid hemorrhage
(tSAH), that is found in a large number of moderate and severe TBI cases and has been
shown to be a negative prognostic factor. This analysis was performed using the primary
data from a recent nationwide phase III randomized controlled trial evaluating
progesterone administration on the outcomes in traumatic brain injury.
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II. LITERATURE REVIEW

Overview
Traumatic brain injury is a major cause of death and disability, both in the United
States and worldwide. Millions of individuals sustain TBIs every year and even more
suffer from long-term effects from these injuries, costing tens of billions of dollars in
care delivered and lost employment potential (Langlois et al., 2006). The specific type of
TBI, traumatic subarachnoid hemorrhage, is both very common in more severe TBI
(occurring in up to two-thirds of moderate and severe cases historically) and associated
with poor outcome, with increased rates of mortality and unfavorable outcomes over
patients without these injuries (Armin, Colohan, & Zhang, 2006, pp. 445–446).
Brain injury research is exceptionally challenging due to many reasons, such as
the difficulty in classifying a heterogeneous injury and the paucity of objective and
clinically relevant endpoints. Many pharmacological agents have been studied to treat
TBI and even a few specifically for tSAH, but none have been shown definitively to
improve outcomes or lower mortality (Maas, Stocchetti, & Bullock, 2008, p. 736; Armin
et al., 2006, p. 445). Significant differences exist between the etiology and
pathophysiology of tSAH and those of aneurysmal subarachnoid hemorrhage (aSAH,
subarachnoid hemorrhage of non-traumatic origin), but there are also meaningful
similarities. Basic science tests in animal subarachnoid hemorrhage (SAH) models have
findings that may translate to human subjects with tSAH (Armin et al., 2006, p. 448).
The hormone progesterone, naturally occurring in both male and female bodies,
has long held promise as a treatment for TBI, with extensive preclinical testing
suggesting that it limits the detrimental secondary injuries sustained in TBI such as
swelling and increased intracranial pressure. Subsequent research has supported the
findings of two small human pilot trials investigating the efficacy of progesterone
therapy for TBI (Espinoza & Wright, 2011). The Progesterone for Traumatic Brain
Injury, Experimental Clinical Treatment (ProTECT III) trial, which began enrolling
subjects in 2009, was the first phase III randomized controlled trial assessing the effect
of progesterone in the setting of traumatic brain injury.
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Existing literature provides theoretical reasoning that progesterone may have a
different treatment effect in TBI patients with tSAH. This investigation analyzed
ProTECT III trial data to evaluate if there is statistical interaction between progesterone
and tSAH. An interaction would be suggested if there were a difference in the rates of
favorable outcomes in the progesterone-treated subjects with tSAH over those without.
This was assessed by measuring mortality and functional outcomes of patients and then
performing a subgroup comparison based on treatment of progesterone or placebo.

Epidemiology and cost of traumatic brain injury
Traumatic brain injury (TBI) is an important public health problem…TBI is
frequently referred to as the ‘silent epidemic’ because the complications from TBI,
such as changes affecting thinking, sensation, language, or emotions, may not be
readily apparent. In addition, awareness about TBI among the general public is
limited. (Faul, Xu, Wald, & Coronado, 2010, p. 5)
Over ten million traumatic brain injuries with the severity to cause death or
hospitalization are estimated to occur worldwide every year (Hyder, Wunderlich,
Puvanachandra, Gururaj, & Kobusingye, 2007). Considering that only a fraction of brain
injuries are of the severity to necessitate hospitalization, the actual total global incidence
of TBI is likely many times higher than this figure; no reliable point estimates of the
worldwide prevalence of TBI could be found in a literature review. The World Health
Organization estimates that “TBI is predicted to become the third leading cause of
global mortality and disability by 2020” due to increasing rates of motor vehicle crashes
(“The changing landscape of traumatic brain injury research,” 2012, p. 651). Though
data from developing countries is sparse and possibly inaccurate, it suggests that lowand middle-income regions have a higher relative burden of injury from TBI than highincome areas, thought to be in part due to lack of safety and health care infrastructure
(Hyder et al., 2007, pp. 341–342). But even in the developed world, where subject
literature is much more prevalent and reliable, it is clear that traumatic brain injury is a
major public health problem.
Based on the Centers for Disease Control and Prevention’s Morbidity and
Mortality Weekly Report, of the estimated 1.7 million people who suffered a TBI each
4	
  

year from 1997-2007 in the U.S., 1.4 million were seen and discharged from the
emergency department (ED), 275,000 were hospitalized and survived, and 52,000 died
(Coronado et al., 2011, pp. 1–2). Total prevalence is much higher—5.3 million
Americans (~ 2% of the entire U.S. population or ~ 10% of those with any permanent
disability) are estimated to be coping with long-term disability from a traumatic brain
injury (Langlois et al., 2006, pp. 376–377). It is estimated that, in the U.S., someone
suffers a TBI every 21 seconds (Hyder et al., 2007, p. 346).
Although anyone (regardless of age, socioeconomic status, comorbidities, or other
factors that typically influence risk) can be susceptible to traumatic injury, populationlevel patterns certainly exist in TBI. Faul et al. (2010) synthesized the ED visitation,
hospitalization, and mortality data of three national databases from 2002 to 2006 to
compile the most comprehensive epidemiological analysis of TBI in the United States to
date. They found those at highest risk for TBI are universally male (i.e. males are the
majority of cases in all subgroups), making up 59% of all identified TBI cases (p.16).
The gender disparity is much more lopsided in some subgroups, such as 20-34 year olds
with fatal injuries, where greater than 80% of the victims are men (p. 38). As with many
other diseases, the young and the old are especially vulnerable. Children aged 14 and
younger make up almost 35% of all ED visits for TBI, and individuals 75 and older have
the highest rates of hospitalization and death of all age groups (p. 7). Falls and motor
vehicle collisions are the most likely causes of fatal injury, and TBI is estimated to
contribute to one-third of all injury-related death (pp. 6-7). Importantly, this frequency
data underestimates the actual burden of brain injury, as it does not include more than a
half million patients. Anyone treated in medical settings outside of the hospital (e.g.
primary care physician visits), any non-civilians (this report does not include data from
federal, military, or VA hospitals), or any of the estimated 25% of TBI patients that seek
no medical care at all, were not included in these figures (pp. 60-61).
The implications of the epidemiology data are profound. Treating significant TBI
in modern medical facilities is very expensive; Farhad et al. (2013) found that the
average hospitalization for brain injury costs more than $20,000 and acute-care hospital
bills can easily rise above $100,000 for the most severe patients (p. 85-86). And these
treatment costs have skyrocketed—the same literature notes a 200% increase in the cost
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of TBI hospitalization between 1993-1994 and 2006-2007, after adjustment for inflation
(Farhad et al., 2013, pp. 85–89). Even “mild” brain injury can have enduring,
debilitating, and sometimes even fatal effects; a prospective cohort study in the United
Kingdom found that around half of brain injury patients aged 14 and over had moderate
or severe disabilities after one year, regardless of the severity of the index injury
(Thornhill et al., 2000, pp. 1631–1633). The spectrum of increasingly-intensive
rehabilitation cost between $50,000 to almost a half of a million dollars per year in
1991, and these figures are unadjusted for a subsequent quarter-century of inflation
(Humphreys et al., 2013, p. 283).
Not only can TBI profoundly change lives through physical disability and personal
and familial financial hardships, but brain injury also has major economic impacts at the
societal level. Just in the United States, the cost of acute TBI care and rehabilitation
paired with the indirect costs of the lost earning potential of patients and other collateral
economic effects are estimated at $60 billion per year (Langlois et al., 2006, p. 377).
More recently, the CDC approximates this figure to be $76.5 billion (Manley & Maas,
2013, p. 473). Though even rough estimates of the worldwide total cost of TBI are
certainly very imprecise without more reliable epidemiologic data, extrapolating existing
cost data to global frequency estimates likely puts the global economic impact of TBI in
magnitude of hundreds of billions of dollars.

Classification and pathophysiology of TBI
Substantial research effort has gone into mitigating the immense burden of TBI,
but it remains an exceedingly complex area of study and clinical trials are fraught with
obstacles in the search for effective treatment (Saatman et al., 2008, p. 720). The term
“traumatic brain injury” is actually a catchall phrase, representing a host of
fundamentally distinct physical insults. There are several major phenotypes of brain
injury, such as hematomas (collection of blood) and axonal injury (shearing of neuronal
cells). These subtypes of TBI vary in the mechanical forces required to inflict them, the
structural damage which occurs to the affected brain cells, the pathophysiological
sequelae occurring as a result of the injury, and the prognosis of the patient (Saatman et
al., 2008; Zhu, Wang, & Liu, 2009).
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Most clinical trials to date have classified severity of brain injury by a mental
status assessment called the Glasgow Coma Scale (GCS), which measures verbal
response, eye opening, and motor response of the patient and compiles the three
components into a score from 3 to 15 (Teasdale & Jennett, 1974). The GCS is performed
soon after injury and a lower score represents a more depressed level of consciousness
and, consequently, a more severe brain injury. “Mild,” “moderate,” and “severe” brain
injury correspond to GCS assessments of 13-15, 9-12, and 3-8, respectively (Teasdale et
al., 2014). According to a workshop described by Saatman et al. (2008), the use of the
GCS has been prevalent due to “its high inter-observer reliability and generally good
prognostic capabilities” (p.721). Despite being simple, fast, and therefore relatively easy
for clinicians to use, the biggest problem with using the GCS to select patients for TBI
research is that it does not discriminate between injuries that are classified differently
using other methods, potentially confounding the assessment of treatments while other
methods of classification “may be more relevant to the neuroprotectant action of a
particular intervention” (Saatman et al., 2008, p. 721).
The literature by Saatman et al. (2008) reviews TBI classification systems for use
in clinical trials, providing alternative methods of brain injury classification to the GCS
include pathoanotomic, pathophysiologic, and prognostic models (p. 720).
Pathoanotomic classification distinguishes between the type and location of injury.
Primarily using imaging diagnostics such as computed tomography (CT) or magnetic
resonance (MR), this method categorizes injuries into four basic types: hematomas
(including epidural, subdural, and intraparenchymal—each are lesions in different
structural areas of the brain), contusions (bruising of the brain tissue), diffuse axonal
injury, or subarachnoid hemorrhage (pp. 722-724). Evidence suggests that mechanism of
injury is correlated with the phenotype of injury sustained; linear and rotational forces
damage the physical structures of the brain differently. “Impact loading,” or contact
forces, usually produce fractures, contusions, and epidural hematomas, while “inertial
loading,” or noncontact forces, are theoretically more likely to cause concussion,
subdural hematomas, and axonal injury (p. 723).
Pathophysiologic classification, very simply put, distinguishes between “primary
injury,” or the direct insult to the brain from the index external force, and “secondary
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injury,” or damage occurring to the brain as a result of the complex injury cascades after
the initial structural damage like swelling and vasospasm (constriction of blood vessels)
(p.724). It is this “potentially avoidable damage that occurs at variable times after
injury” that research efforts have attempted to target for pharmacological treatment
(p.723).
Finally, prognostic classification uses complex multivariate statistical modeling to
choose the factors with the strongest associations with outcomes to create a hybridized
scoring system like the International Mission for Prognosis and Analysis of Clinical
Trials in TBI (IMPACT) model, which uses data points from demographics, clinical
assessments, brain imaging, and laboratory values to predict outcome in TBI (pp. 732733).

Other obstacles in TBI research and past clinical trials
Leading neurotrauma researchers believe that historical and contemporary
attempts to translate basic science findings into human clinical research have failed in
part due to the inadequacy of prevalent classification systems and an inability to develop
effective methodology to account for the heterogeneity of TBI (Yue et al., 2013). A
multitude of other obstacles exist in clinical trials for brain injury. Randomized
controlled trials (RCTs) are considered to be the “gold standard” in pharmacological
efficacy trials, yet they are very expensive to conduct and research funding is limited
(Roozenbeek, Lingsma, & Maas, 2012). Lack of standardization of data elements
between trials limits the ability to combine data sets to achieve higher statistical power
for post hoc analyses (Maas et al., 2011, p. 178). Typical outcome measures specific to
TBI can be subjective and prone to bias and significant inter-rater variability. Other
outcome assessments, such as neuropsychological tests, were not developed or validated
for use in TBI patients. Outcomes measured at 6-months (the predominant follow-up
time point in most TBI RCTs) are not taking into account long-term functional outcome,
which have shown that many problems or improvements are still manifest up to three
years from injury (van Baalen et al., 2003). Lastly, the Glasgow Outcome Scale (GOS)
and its successor, the Extended Glasgow Outcome Scale (GOSE), the primary outcome
measure used most frequently in brain injury clinical trials, may be inadequate in
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assessing cognitive outcome and often are analyzed in ways that fail to maximize
statistical power (Alali et al., 2014, pp. 1–2).
As a result of these factors along with inadequate preclinical testing, flawed study
design, and insufficient evaluation of pharmacological biomechanics to target the
complex cascade of secondary brain injury have lead to a veritable graveyard of
experimental clinical trials in TBI (Kabadi & Faden, 2014, pp. 1216–1219). At least 33
phase III clinical trials have been performed for traumatic brain injury since 1980, the
majority of which tested a pharmacological agent (Maas, Roozenbeek, & Manley, 2010,
p. 116). In total, none of the more than 20 promising neuroprotective agents “have
convincingly shown efficacy in the overall study population” for the treatment of TBI
(Maas et al., 2008, p. 736). Several trials have evaluated efficacy of two drugs,
milrinone and nimodipine, specifically in the subgroup of TBI with traumatic
subarachnoid hemorrhage (tSAH), but conclusive benefit has not been shown for either
agent in the treatment of tSAH (Lasry & Marcoux, 2014; Vergouwen, Vermeulen, &
Roos, 2006). Despite the obvious negative of the inability to find a treatment for the
injury that continues to kill and disable so many, the consistent failure of
pharmacological TBI clinical trials seems to be hindering the further development of
investigations despite promising new agents (Maas et al., 2010, p. 119).

Progesterone for the treatment of TBI
Long thought to be “a simple reproductive hormone” on account of its dramatic
rise in females during gestation, the neurosteroid progesterone has been studied
extensively in the context of TBI (Donald G. Stein & Wright, 2010, p. 849).
Progesterone was first identified as having a potential effect in brain injured rats more
than 20 years ago, after disparities in outcomes were seen relative to gender (Roof,
Duvdevani, & Stein, 1992). Evidence suggests that progesterone acts in multiple ways to
ameliorate sequelae of the complex biochemical chain of events that make up secondary
brain injury. This pleiotropic effect of the hormone gave rise to the hope that it would
succeed where many, more specifically-acting therapies had previously failed (Espinoza
& Wright, 2011, pp. 497–498).
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Briefly, progesterone has been shown in basic science tests to reduce cerebral
edema, enhance neuronal survival, attenuate inflammatory pathways, reduce oxidative
stress, and modulate receptor pathways, leading to improved functional outcome and
limiting “behavioral, cognitive, and sensorimotor deficits” (Deutsch et al., 2013, pp. 88–
89). The hormone was evaluated in over 180 preclinical brain injury trials and two phase
II human trials (where it was deemed safe to continue with further testing) prior to the
large clinical trials of ProTECT III and the Study of the Neuroprotective Activity of
Progesterone in Severe Traumatic Brain Injuries, or SyNAPSE trial (D.G. Stein, 2011,
pp. 104–105). Two other pilot trials of progesterone in humans with TBI were found in
the literature, in addition to those mentioned by Stein (2011). Those trials also suggest
that progesterone may improve outcomes in brain injured patients (Xiao et al., 2007;
Shakeri et al., 2013).

ProTECT III and SyNAPSE trials
The ProTECT III study was a National Institute of Neurological Disorders and
Stroke (NINDS)-funded clinical trial to determine if progesterone is effective in
improving outcomes in moderate and severe TBI. Subjects included had an initial GCS
between 4 and 12 while those with confounding events, such as significant hypoxia (low
oxygen) or hypotension (low blood pressure) or signs such as two dilated and unreactive
pupils (all of which are prognosticators of poor outcomes), were excluded. Because the
ProTECT pilot trial suggested that subjects receiving progesterone most quickly might
have the best response to the intervention, study treatment was delivered within four
hours after the injury.
Subjects were monitored closely throughout their hospitalization, and treatment
teams adhered (as closely as possible) to clinical care guidelines with the hopes of
standardizing treatment and minimizing variability in the almost 50 sites nationwide that
participated in the trial. The primary outcome for the trial was the 6-month GOSE
assessment, and results were stratified to account for severity of initial injury.
Enrollment for the trial was halted after randomizing 882 subjects, out of the planned
sample of 1140, on account of futility to prove its primary hypothesis. Progesterone was
not found to have a significant effect on the outcomes of moderate and severe traumatic
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brain injury patients (Wright et al., 2014). Beginning enrollment one year after
ProTECT III, the SyNAPSE trial was similarly structured except that it enrolled only
severe TBI patients (those with a GCS ≤ 8). This research also did not show significant
benefit for the intervention to improve outcomes in the study sample (Skolnick et al.,
2014). Primary analyses for these trials were published together in the New England
Journal of Medicine in December of 2014.

Traumatic subarachnoid hemorrhage
The arachnoid mater is one of the three meningeal layers of the brain, which lie
underneath the skull and cover the brain cortex. Cerebrospinal fluid normally circulates
in the space below the arachnoid mater. If there is hemorrhagic insult to the vasculature
surrounding the brain, blood can collect there, hence the name of subarachnoid
hemorrhage (SAH) (Bear, 2007, pp. 173–174). There are many different etiologies for
SAH, but the two main causes are aneurysmal (as it is usually due to the rupture of an
aneurysm), or as a result of trauma (aSAH and tSAH, respectively) (Suarez, Tarr, &
Selman, 2006, p. 387). The medical community refers to and studies these two
classifications of SAH as different diseases, though evidence suggests they have
pathologic characteristics in common such as vasospasm and ischemia (decreased
oxygen delivery to tissue) (Fukuda, Hasue, & Ito, 1998; Taneda, Kataoka, Akai, Asai, &
Sakata, 1996). In previous studies, tSAH is seen on initial brain imaging between 33 and
67 percent of severe head injury patients (Kakarieka, Braakman, & Schakel, 1994, p. 2;
Bobinski, Olivecrona, & Koskinen, 2012, p. 1072).
Though there is much variation in the literature of the prevalence of this specific
finding, it is not the only inconsistency in tSAH-specific research. As with general study
of TBI, assessments of the pathophysiology of tSAH are confounded on account of
concomitant injuries and other covariates (Armin et al., 2006, p. 446). The correlation of
tSAH and worsened outcomes, however, seems to be universal. A host of manuscripts
exist supporting this association in brain-injured patients; one investigation saw a rise in
mortality in severe TBI patients from 14% to 42% from those that did not have evidence
of tSAH to those that did (Kakarieka et al., 1994, p. 3). But there is disagreement on
whether this relationship is directly or indirectly caused by the tSAH itself (Mattioli et
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al., 2003, p. 40). Conflicting data is responsible for this uncertainty, but two basic
possibilities exist: tSAH is an independent prognosticator of outcome, or it is merely
representative of a more severely injured patient and not responsible for increased
morbidity and mortality outright (Armin et al., 2006, pp. 446-447).
Some of the early research in this area suggested that, as with aSAH, patients with
tSAH are at risk for vasospasm and resultant cerebral ischemia—pathophysiology that
would likely explain the worsened clinical outcomes in this population (Harders,
Kakarieka, & Braakman, 1996, p. 82). Subsequent analysis has found associations
between tSAH and more parenchymal damage, higher intracranial pressures, and
inflammatory processes (such as swelling and edema), and concluded these sequelae are
responsible for poorer outcomes in these patients rather than the tSAH or resultant
vasospasm and ischemia itself (Servadei et al., 2002, p. 266). Recent review remains
inconclusive exactly what role vasospasm plays in outcomes in tSAH patients (Kramer,
Winer, Pease, Amar, & Mack, 2013, pp. 3–4). Even the most current literature
acknowledges that the complex pathophysiology of secondary brain injury in tSAH
remains incompletely understood, though relative certainty exists that tSAH is a
prognosticator for poor outcomes (Servadei & Picetti, 2014 pp. e597-e598).

Theoretical basis for hypothesis
As previously mentioned, the literature supports beneficial effects of progesterone
administration in the setting of brain injury as well as a host of other neurological
conditions “including ischemia, spinal cord injury, peripheral nerve injury, motorneuron
disease, demyelinating disease, and seizures” (Deutsch et al., 2013, p. 83). Though none
of the six clinical trials studying progesterone in TBI found in the literature have
specifically assessed tSAH until now, a number of studies have investigated
progesterone’s effect in SAH in animal models. Although these studies were designed to
assess the affects of progesterone in aSAH, it is recognized that aSAH is not
pathophysiologically identical to tSAH with clinically meaningful differences between
the two conditions. It also cannot be assumed there is no translation of findings
whatsoever from aSAH to tSAH. Furthermore, Armin et al. (2006) assert, “the
traditional animal experiments that had originally sought to investigate vasospasm in
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relation to aSAH may be considered to actually have been mimicking tSAH” (p. 448).
Another review concluded that tSAH was the most reproducible of five different lesion
types in multiple animal models of injury (Doppenberg, Choi, & Bullock, 2004, p. 87).
Although the exact characteristics and effects of vasospasm in tSAH require
further evaluation, it is generally agreed that it does occur; one estimate of prevalence of
vasospasm in tSAH to be between 25-30% of patients (Fukuda et al., 1998, p. 1044).
Progesterone has been shown to significantly attenuate vasospasm in rats with induced
aSAH (Chang et al., 2014). If vasospasm is contributing, at least in part, to worsened
outcomes in tSAH, then it is possible that progesterone may benefit this population. But
it is progesterone’s varied and multiple mechanisms of neuroprotection that set it apart
from most of the other experimental pharmacologic agents, which have more limited
methods of action.
In addition to acting on vasospasm, progesterone ameliorates secondary injuries
frequently found in tSAH. Wang et al. (2011) showed that, through complicated
biochemical processes, progesterone affects the inflammatory response after the
induction of SAH (p. 4). Thus this had important and clinically relevant effects on
outcomes. Rats given progesterone showed statistically significant improvement on
behavior function performance after SAH. Water content of the brains was significantly
less in the progesterone-treated group, suggesting that cerebral edema (a common and
potentially sinister finding in SAH and TBI in general) may be lessened by the
intervention. Finally, this research demonstrated that progesterone significantly limits
the permeability which develops in the blood-brain barrier (BBB) (pp. 6–8). The BBB
is a specialization of the capillaries of the brain that regulate the passage of molecules
from the blood into the brain, thus prohibiting the entry of bacteria and other blood
borne substances (Bear, 2007, p. 71). In fact, cerebral edema and the disruption of the
BBB are likely directly related (Unterberg, Stover, Kress, & Kiening, 2004). A more
recent study confirmed the findings of the previous investigations into the effects of
progesterone in the setting of SAH in the animal model, finding a reduction in cell
apoptosis (“self destruction” of cells, put simply), edema, BBB disruption, and
mortality, with improved neurological and functional outcomes in those that survived
(Yan et al., 2013, pp. 165–167).
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The preclinical evidence regarding progesterone in SAH shows promise for the
intervention to improve functional outcomes and decrease mortality in TBI patients if
these mechanisms translate to humans. If the theories of how progesterone acts to reduce
secondary brain injury are correct, then perhaps progesterone will be effective in an
analysis of the subgroup with tSAH findings on initial brain imaging in the ProTECT III
clinical trial data, despite the negative findings of the drug in the total study sample.
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III. MANUSCRIPT
Background
Traumatic brain injury (TBI) is a major cause of death and disability; approximately
1.7 million people sustain a TBI every year in the United States—52,000 of these injuries
are fatal.1 Indirect and direct costs of TBI in America are estimated to be $60-75 billion
per year.2,3 Research of interventions for acute care of TBI is difficult, largely due to the
heterogeneity of injury and complex pathophysiology of neurotrauma.4 At least 20
pharmacological agents have been tested in phase III clinical trials over the last 30 years
and none have shown convincing efficacy in treating TBI.5
Radiological findings of subarachnoid hemorrhage (SAH), or blood in the
subarachnoid meningeal space, on initial computed tomography (CT) imaging are found
in one- to two-thirds of more severely brain-injured patients.6,7 The presence of
subarachnoid hemorrhage caused by trauma (tSAH) is associated with increased
mortality 6,8,9 and worsened functional outcome,10–13 though there is still uncertainty if
tSAH is an independent prognosticator (possibly through mechanisms such as
vasospasm14 or ischemia15) or an epiphenomenon.16,17
The endogenous hormone, progesterone (PROG), has been evaluated in over 180
preclinical brain injury studies showing neuroprotection.18 Four human pilot trials19–22
have showed that PROG may improve outcomes in TBI, but these trials were not
powered for conclusive results. Evidence suggests that PROG is pleiotropic, acting
through multiple neuroprotective mechanisms to attenuate several characteristics of
secondary brain injury associated with both SAH and worsened clinical outcomes in
animal models. PROG has been shown ameliorate several sequelae of tSAH in preclinical
studies: reduction of vasospasm,23 decreased inflammatory response, cerebral edema, and
permeability of the blood-brain barrier,24 and limitation of cell apoptosis,25 all of which
reduce mortality and improve functional and neurological outcomes after SAH.
Two recent phase III trials failed to show benefit of PROG over placebo for study
subjects with a severe or moderate-to-severe TBI.26,27 As of this writing, no published
studies were found that investigate PROG specifically for the treatment of SAH of either
traumatic or non-traumatic etiology in humans. This exploratory analysis of data
collected in the Progesterone for Traumatic Brain Injury Experimental Clinical Treatment
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(ProTECT III) study, a multicenter randomized controlled trial, is in response to this gap
in the science. Since PROG may exert a different mechanism of action in TBI with tSAH
due to changes in cellular pathophysiology and the blood-brain barrier, the objective of
the present study is to determine if the effect of PROG administration in subjects with
moderate and severe TBI is different in those with evidence of tSAH on baseline CT
radiology compared to subjects without tSAH.

Methods
Design & participants
This analysis is a post hoc examination of trial data from the
ProTECT III clinical trial.26 Eight hundred eighty-two subjects, out of
the planned sample of 1140, were enrolled in the study before
recruitment was halted when a scheduled interim analysis determined
it would not be able to show PROG efficacious for the treatment of
study subjects with a moderate or severe TBI. See Appendix 1 for the
ProTECT III protocol summary.
Subjects included in this analysis were adults with a blunt
mechanism TBI and an initial Glasgow Coma Scale (GCS) of 4 to 12.
The GCS is a mental status assessment that judges eye, verbal, and
motor response—these 3 components are summed to reach the total GCS score, a
composite number from 3 to 15. A lower score represents more severe brain injury
(Figure 1). This scale was developed specifically to quantify TBI severity,28 but its use
has become common for all types of patients in emergency departments and intensive
care units worldwide and has high predictive capabilities and inter-rater reliability.29
As is typical with trauma patients suspected of having a TBI, all of the subjects in
this study received a CT scan as soon as possible after arrival at the enrolling trauma
center. An independent neuroradiologist assessed all images and documented any
findings indicative of acute brain injury in the study database (see Supplement 1 for the
radiology case report form from the trial). Major phenotypes of injury assessed (in
addition to tSAH) were epidural, subdural, and intraparenchymal hematomas, brain
contusions, diffuse axonal injury, and cranial fractures. Secondary injury characteristics
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documented were signs of increased intracranial pressure, cerebral edema, or localized
swelling.
All ProTECT III subjects with at least one abnormality noted on baseline CT were
included in the present analysis. Those subjects in the parent trial that had no
abnormalities on initial brain imaging or missing this scan altogether were excluded from
the current study. The total sample, participants with abnormal radiological findings, was
labeled CT positive (+CT). +CT subjects were then divided into two subgroups by
presence or absence of the independent variable in question for this analysis, tSAH.
Subjects were included in the tSAH positive (+tSAH) group if their radiology showed
any evidence of subarachnoid blood defined as hemorrhage of any severity in one or
more of the locations assessed (the suprasellar or basal cisterns; the Sylvian,
interhemispheric, or lobar fissures; or the ventricular system). Subjects in the tSAH
negative group (–tSAH) had no instance of any of the findings above. Any other
abnormal CT findings had no bearing on subgroup allocation and +tSAH or –tSAH
subjects could have any combination of concomitant injuries evident on baseline CT.
Each subgroup was further divided upon which study treatment subjects received, PROG
or placebo. Figure 2 is a diagram detailing the sample selection in the study.
Figure	
  2.	
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Intervention
Study medication was administered as soon as possible after enrollment, but within
4 hours. Progesterone and placebo were identical in appearance and packaging.
Treatment infused for 96 hours, starting with a one-hour loading dose, then a 71-hour
maintenance dose, and finally a 3-tiered taper with 8 hours at each step until the infusion
was complete.
Outcome and other measurements
The GOSE assessment was used as the primary outcome for this study. It ranks the
functional outcome of brain injury patients into one
of eight different categories30 (Figure 3). There are
different statistical models used to analyze this
measurement,31 but we chose a fixed dichotomy,
which classifies a GOSE score of ≤ 4 as unfavorable
and 5 or above as favorable, or more functionally
capable. This method was chosen based on convention,31 historical statistical distribution
of outcomes,5 improved generalizability of results,32 and that covariate adjustment in
well-balanced subgroups of RCTs is not likely to significantly change the results from an
unadjusted model.33
Other classification systems used in this report are as follows. The Abbreviated
Injury Scale (AIS) is an ordinal measurement from 1 to 6 for each of nine body regions.34
It is based on severity and location of injury and a score of 1 represents minor injury
while 6 is a fatal injury). The Injury Severity Score (ISS) is directly computed from the
AIS, squaring the highest 3 values; a score of 75 is the maximum.34 Finally, the
Rotterdam CT classification is a prognostic assessment (also 1 to 6, with a higher score
correlating with increased mortality) developed in part to account for the strong
prognostic value of tSAH and improve the accuracy of previously-existing predictive
models for outcome in TBI.35,36 Other variables known to correlate with outcome in TBI
that were considered in this analysis are age, GCS, pupil reactivity,37 significant postinjury hypoxia or hypotension38, and the presence of polytrauma (significant injuries in
multiple body systems).39
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Randomization
Subjects were randomized to treatment group either PROG or placebo, in a 1:1
ratio. Age and GCS were factored into randomization scheme in order to assure even
population of initial risk stratifications and gross age distribution between treatment
groups. Randomization assignment was double-blinded so that none of the clinicians or
researchers, in addition to subjects or their friends and family, knew which treatment
study participants were receiving. Blinding remained throughout the study
Statistical analysis
We compared patient characteristics by treatment assignment to assess the
distribution of covariates; comparisons were performed for all eligible participants and by
tSAH classification. Risk ratios (RRs) and 95% confidence intervals (CI) were calculated
based on the number of subjects with a favorable outcome relative to PROG for each
subsample. Subjects missing outcome data were excluded entirely from the analysis. For
the primary analysis, we compared the effect of progesterone on risk of favorable
outcome by tSAH classification to assess interaction. In secondary analyses, we used
Poisson log regression to estimate an adjusted RR, controlling for covariates. Variables
included in the regression analysis were chosen based on uneven treatment distribution at
baseline regarding prognostic and clinical characteristics: age, race, mechanism of injury,
and pre-randomization hypotension were included in the adjusted regression model.

Results
Of the 882 subjects enrolled in the ProTECT III trial, 756 had abnormalities present
on baseline CT images; 125 were excluded from analysis because abnormalities were not
present, and one subject did not have an image collected. Five hundred eighty-two
subjects, or 66% of all of the subjects in the parent trial, had evidence of tSAH on CT.
Treatment group prevalence within the +tSAH and –tSAH subgroups was even to within
5%. Table 1 shows demographic distributions, causative mechanism for TBI, and mean
times from injury across the subgroups (since receiving expedient care and timely
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delivery to the hospital is beneficial to outcome for neurotrauma patients).40
The median age in the +tSAH group was 39 (range 17-93) compared to a median of 30 in
the -tSAH group (range 17-94) and 36 among all enrolled participants (range 17-94).
Gender distribution was almost exactly the same for all groups—males outnumbered
females nearly 3 to 1. The largest variations were shown between treatment groups in the
mechanisms of injury and in the smaller –tSAH group where age and race were
substantially different (Table 2).
Injury severity was greater in the +tSAH group over the –tSAH group by all
classification systems reported; absolute differences of +tSAH minus –tSAH were
GCS, -0.6; AIS, +0.4; Rotterdam, +1.1; and mean ISS, +3.7 (Table 3). All subgroups and
the entire sample had mean Injury Severity Scores (ISS) well above 15, typically
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considered the standard threshold for polytrauma.39 Concomitant intracranial injuries
were largely disparate in the two subgroups, with the +tSAH group having greater
prevalence of all other main categories of abnormalities assessed on baseline CT. These
findings ranged from a 2.2% increase of diffuse axonal injury in +tSAH over –tSAH to
an almost 19% higher frequency of cerebral edema. Even in the –tSAH group, although
less-severely injured as a whole, showed particularly high numbers of subdural
hematomas (SDH) and skull fractures, occurring in approximately half of the subgroup
sample.
Injury distributions between the treatment assignments were within 5% in the
+tSAH group for all phenotypes. The PROG-treated subjects in the –tSAH group had
5.5% more skull fractures, 6% more brain contusions, and 12.6% more SDHs (Table 4).
All severity classifications however, were nearly identical between treatment groups.

+tSAH subjects did markedly worse than -tSAH, with an almost 27% shift from
favorable to unfavorable outcome between the groups (Table 5). +tSAH subjects had a
10.3% higher mortality rate than –tSAH subjects, and 2.4% more than total sample.
Although modest improvements in favorable outcomes were seen in the PROG treatment
group between subgroups (1.4% increase in absolute rate of favorable outcome of +tSAH
over –tSAH), mortality was also higher in the PROG-treated subjects regardless of
grouping (+tSAH 2.7%, –tSAH 2.3%, +CT 2.1%; Table 6 & Figure 4).
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The RRs in Table 7 show progesterone had a modest favorable effect in both the
unadjusted and adjusted analyses. In the unadjusted analysis, the risk of a favorable
outcome with PROG in the +tSAH group is 1.06 times that of subjects receiving placebo
(95% CI 0.89 to 1.26). Risk for favorable outcome in the –tSAH group for PROG was
1.02 (95% CI 0.85 to 1.22) times that of subjects receiving placebo. After adjustment,
RRs show that the risk of a favorable outcome of +tSAH patients treated with PROG to
be 1.07 times that of placebo; PROG-treated subjects had 1.08 times the risk of a
favorable outcome in the –tSAH group, but not +CT (and less absolute difference
between all groups). However, these RRs were not statistically significant.

Discussion
Overall, we found +tSAH patients receiving progesterone therapy had a 2.8%
greater likelihood of favorable outcome compared to +tSAH patients receiving placebo.
Favorable outcome for PROG-treated subjects was 1.4% and 1.9% more likely in the
–tSAH and +CT groups (respectively). Unadjusted estimates of relative benefit of PROG
are 1.06 over placebo for +tSAH and 1.02 in the –tSAH sample. The small differences
measured in treatment effect are not enough to suggest that tSAH changes the effect of
progesterone in the treatment of TBI as postulated.
Mortality rates of subjects with tSAH on brain imaging in this analysis (23%) are
comparable to those in a 2006 systematic review of nimodipine for the treatment of
tSAH39 (26%), although a smaller proportion of participants experienced an unfavorable
outcome compared to what we report in the present study (40% vs. 53%). This
discrepancy is likely due to differences in inclusion criteria between the studies, and the
authors did not detail the characteristics that made patients eligible for enrollment. The
review did not show a significant treatment effect of nimodipine in tSAH. Another
investigation of milrinone specifically for vasospasm in tSAH41 was not powered to draw
any worthwhile conclusions. With 756 subjects, our study was the largest single analysis
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found in the clinical trial literature evaluating an intervention specifically in the setting of
tSAH (the next largest was the unpublished HIT 4 trial with 577 subjects42).
Some differences present in the distribution of baseline patient characteristics in this
study could be meaningful. The –tSAH group was younger than the rest of the sample
and, within this smaller subgroup, there was a large age difference between the treatment
assignments. Age has been shown to be a specific and powerful measure for outcome in
brain injury.36 Additionally, given recent literature suggesting that tSAH patients in
motor vehicle collisions may have poorer outcomes than those that fall from height (> 3
feet),43 it is reasonable to adjust for the mechanism of injury in the multivariate analysis
given variability in frequencies across treatment groups. Two related conclusions can be
drawn from the evenness of subgroup and treatment groups with regards to most of the
key prognosticators, injury patterns, and even subjects with missing outcome:
randomization of the parent trial was very effective, and minimal (if any) adjustment
should be necessary to answer the research question proposed.
If the unadjusted model is believed to be the most reliable computation (with even
sample distribution as exhibited here), then it is possible that additional research,
potentially in a prospective trial design, could be considered to further examine the
possibility that PROG could improve outcome in patients with tSAH on baseline CT
imaging. Of course the possibility that PROG may increase mortality should also be
considered (although any adjustment for neurological vs. non-neurological [i.e. subject
died from something else than TBI] was not factored into this analysis).
The basic prevalence of +tSAH and –tSAH in this analysis supports previously
existing research findings that tSAH incidence is disproportionate among more-severely
injured TBI patients.6,7 However, the statistical models used here did not attempt to
determine the underlying reason for this imbalance and no inferences can be made
regarding why rates of favorable outcomes are lower in patients with evidence of tSAH
on CT imaging from these data from those without signs of the injury. Obviously, it is
expected that more severe TBI and higher prevalence of concomitant injuries will lead to
poorer outcome. But it remains unanswered whether tSAH is an independent cause of
worsened outcomes (possibly by associated secondary brain injury), or only correlated
with other structural damages that are the responsible factors.
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The present study has several important limitations worth noting. First,
interpretation of subgroup analyses not specified in the original trial design should be
critical due to a host of publicized issues such as low power, inappropriate statistical
models, potential for type I error, and assumptive conclusions.44,45 Nonetheless, TBI is a
heterogeneous disease with multiple underlying pathologies and there was biologic
plausibility for our research question in the context of exploratory analysis and
hypothesis generation. We did not perform a statistical interaction test because it was
likely to result in misleading results or misinterpretation of its p-value in this post hoc
subgroup analysis.33,46 Due to the fact that this study was exploratory with the intention
of generating a hypothesis rather than testing one, clinical care recommendations or
treatment guidelines should not be drawn from this analysis. Second, potentially
important confounding covariates were not included in this analysis and, if there were
large differences in treatment distribution, it is possible that our effect estimates were
biased. For example, although the ProTECT III trial attempted to control treatment
variability with clinical care guidelines for study subjects, significant differences have
been found in previous studies between trial enrolling sites.38 No consideration was made
here to assess or account for discrepancies between hospitals that were unlikely to have
occurred by chance, if they indeed exist in the parent trial data. Also, significant
complications in the patients’ hospital course can drastically effect outcome; although
data regarding severe adverse events and deviations from treatment guidelines were
collected, these data had not yet been properly processed at the time of the present
analysis and thus could not be included herein. Third, subsequent imaging was also not
included in this analysis, but could reveal important findings not visible on baseline CT
such as diffuse axonal injury or hemorrhage expansion likely to be detrimental to the
patient’s condition.
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Conclusion
In addition to the recent trials investigating PROG for TBI that showed no benefit
in improving patient outcome, this study also suggests no significant treatment effect of
PROG for tSAH. Although there was improvement shown in a dichotomous 6-month
GOSE assessment to subjects given PROG in all groups in this analysis, this was not
significant nor was an interaction effect noted between PROG and tSAH, as postulated in
the objective for this study. Additional analyses should be performed using the full
transgression and adverse event data, serial biomarker levels, and post-baseline imaging
data to attempt to better determine why patients with tSAH have such poor outcomes
when compared to those without the injury. Further research is needed to explore possible
mitigators of secondary damage and other causes of worsened outcome in individuals
suffering from acute brain injury as a result of trauma.
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Supplement 1
ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
1

Date of scan

__ __ - __ __ __ - __ __ __ __ (dd-mmm-yyyy)

2

Time of scan

__ __ : __ __ (24 hour clock hh:mm)

3

What type of scan was performed?

O MRI

O CT

4

Was the scan technically satisfactory?

O No

O Yes

5

Were there any abnormal findings?
If no, form is complete

O No

O Yes

O No

O Yes
O Yes

Intracranial Bleeding
6

Were there any epidural hematoma findings?
If no, skip to 12.

Protect version 3 27Jan2012

Epidural Hematoma—Frontal
7A

Frontal - Left?

O No

7B

Frontal - Left Depth

__ __ __ (mm)

7C

Frontal - Left Width

__ __ __ (mm)

7D

Frontal - Right?

O No

7E

Frontal - Right Depth

__ __ __ (mm)

7F

Frontal - Right Width

__ __ __ (mm)

O Yes

Epidural Hematoma—Temporal
8A

Temporal - Left?

O No

O Yes

8B

Temporal - Left Depth

__ __ __ (mm)

8C

Temporal - Left Width

__ __ __ (mm)

8D

Temporal - Right?

O No

8E

Temporal - Right Depth

__ __ __ (mm)

8F

Temporal - Right Width

__ __ __ (mm)

O Yes

Epidural Hematoma—Parietal
9A

Parietal - Left?

O No

9B

Parietal - Left Depth

__ __ __ (mm)

9C

Parietal - Left Width

__ __ __ (mm)

9D

Parietal - Right?

O No

9E

Parietal - Right Depth

__ __ __ (mm)

9F

Parietal - Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina
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O Yes

O Yes

O CTA

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Form 03: Radiology Assessment– Central Reader (version 3)
Epidural Hematoma—Occipital
10A

Occipital - Left?

O No

O Yes

10B

Occipital - Left Depth

__ __ __ (mm)

10C

Occipital - Left Width

__ __ __ (mm)

10D

Occipital - Right?

O No

10E

Occipital - Right Depth

__ __ __ (mm)

10F

Occipital - Right Width

__ __ __ (mm)

O Yes

Protect version 3 27Jan2012

Epidural Hematoma—Posterior fossa
11A

Posterior fossa - Left?

O No

11B

Posterior fossa - Left Depth

__ __ __ (mm)

11C

Posterior fossa - Left Width

__ __ __ (mm)

11D

Posterior fossa - Right?

O No

11E

Posterior fossa

- Right Depth

__ __ __ (mm)

11F

Posterior fossa - Right Width

__ __ __ (mm)

Were there any subdural hematoma findings?
If no, skip to 19

O No

O Yes
O Yes

12

O Yes

O Yes

Subdural Hematoma—Frontal
13A

Frontal - Left?

O No

13B

Frontal - Left Depth

__ __ __ (mm)

13C

Frontal - Left Width

__ __ __ (mm)

13D

Frontal - Right?

O No

13E

Frontal - Right Depth

__ __ __ (mm)

13F

Frontal - Right Width

__ __ __ (mm)

O Yes

Subdural Hematoma—Temporal
14A

Temporal - Left?

O No

14B

Temporal - Left Depth

__ __ __ (mm)

14C

Temporal - Left Width

__ __ __ (mm)

14D

Temporal - Right?

O No

14E

Temporal - Right Depth

__ __ __ (mm)

14F

Temporal - Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina
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O Yes

O Yes

Scan
received?
Data Collected?

O No

O Yes

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
Subdural Hematoma—Parietal
15A

Parietal - Left?

O No

O Yes

15B

Parietal - Left Depth

__ __ __ (mm)

15C

Parietal - Left Width

__ __ __ (mm)

15D

Parietal - Right?

O No

15E

Parietal - Right Depth

__ __ __ (mm)

15F

Parietal - Right Width

__ __ __ (mm)

O Yes
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Subdural Hematoma—Occipital
16A

Occipital - Left?

O No

O Yes

16B

Occipital - Left Depth

__ __ __ (mm)

16C

Occipital - Left Width

__ __ __ (mm)

16D

Occipital - Right?

O No

16E

Occipital - Right Depth

__ __ __ (mm)

16F

Occipital - Right Width

__ __ __ (mm)

O Yes

Subdural Hematoma—Posterior fossa
17A

Posterior fossa - Left?

O No

O Yes

17B

Posterior fossa - Left Depth

__ __ __ (mm)

17C

Posterior fossa - Left Width

__ __ __ (mm)

17D

Posterior fossa - Right?

O No

17E

Posterior fossa

- Right Depth

__ __ __ (mm)

17F

Posterior fossa - Right Width

__ __ __ (mm)

O Yes

Subdural Hematoma—Tentorial
18

Tentorial

O No

O Yes

19

Were there subarachnoid hemorrhage findings?
If no skip to question 29.

O No

O Yes
O Yes

Subarachnoid Hemorrhage - Suprasellar
20B

Suprasellar - Present?

O No

20C

Suprasellar - Fisher Grade

O (2) < 1 mm thick

O (3) ≥ 1 mm thick

Subarachnoid Hemorrhage - Basal Cisterns
21B

Basal Cisterns - Present?

O No

21C

Basal Cisterns - Fisher Grade

O (2) < 1 mm thick

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina
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O Yes
O (3) ≥ 1 mm thick

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
Subarachnoid Hemorrhage - Sylvian fissure
22B

Sylvian fissure - Left?

O No

O Yes

22C

Sylvian fissure - Left Fisher Grade

O (2) < 1 mm thick

22D

Sylvian fissure - Right?

O No

22E

Sylvian fissure - Right Fisher Grade

O (2) < 1 mm thick

O (3) ≥ 1 mm thick

O Yes
O (3) ≥ 1 mm thick

Subarachnoid Hemorrhage - Interhemispheric
23B

Interhemispheric- Left?

O No

O Yes

23C

Interhemispheric- Left Fisher Grade

O (2) < 1 mm thick

23D

Interhemispheric- Right?

O No

23E

Interhemispheric- Right Fisher Grade

O (2) < 1 mm thick

O (3) ≥ 1 mm thick

O Yes
O (3) ≥ 1 mm thick
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Subarachnoid Hemorrhage - Lobar - frontal
24B

Lobar - frontal- Left?

O No

O Yes

24C

Lobar - frontal- Left Fisher Grade

O (2) < 1 mm thick

24D

Lobar - frontal- Right?

O No

24E

Lobar - frontal- Right Fisher Grade

O (2) < 1 mm thick

O (3) ≥ 1 mm thick

O Yes
O (3) ≥ 1 mm thick

Subarachnoid Hemorrhage - Lobar - parietal
25B

Lobar - parietal- Left?

O No

O Yes

25C

Lobar - parietal- Left Fisher Grade

O (2) < 1 mm thick

25D

Lobar - parietal- Right?

O No

25E

Lobar - parietal- Right Fisher Grade

O (2) < 1 mm thick

O (3) ≥ 1 mm thick

O Yes
O (3) ≥ 1 mm thick

Subarachnoid Hemorrhage - Lobar - occipital
26B

Lobar - occipital- Left?

O No

26C

Lobar - occipital- Left Fisher Grade

O (2) < 1 mm thick

26D

Lobar - occipital- Right?

O No

26E

Lobar - occipital- Right Fisher Grade

O (2) < 1 mm thick

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina
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O Yes
O (3) ≥ 1 mm thick

O Yes
O (3) ≥ 1 mm thick

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
Subarachnoid Hemorrhage - Lobar - temporal
27B

Lobar - temporal- Left?

O No

O Yes

27C

Lobar - temporal- Left Fisher Grade

O (2) < 1 mm thick

27D

Lobar - temporal- Right?

O No

27E

Lobar - temporal- Right Fisher Grade

O (2) < 1 mm thick

28

Were there intra-ventricular hemorrhage findings?

O No O Yes, minimal layering O Yes, clot

29

Were there any intraparenchymal hematoma findings?
If no, skip to 37.

O No

O Yes
O Yes

O Yes
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Intraparenchymal Hematoma—Frontal
30A

Frontal - Left?

O No

30B

Frontal - Left Depth

__ __ __ (mm)

30C

Frontal - Left Width

__ __ __ (mm)

30D

Frontal - Right?

O No

30E

Frontal - Right Depth

__ __ __ (mm)

30F

Frontal - Right Width

__ __ __ (mm)

O Yes

Intraparenchymal Hematoma—Temporal
31A

Temporal - Left?

O No

31B

Temporal - Left Depth

__ __ __ (mm)

31C

Temporal - Left Width

__ __ __ (mm)

31D

Temporal - Right?

O No

31E

Temporal - Right Depth

__ __ __ (mm)

31F

Temporal - Right Width

__ __ __ (mm)

O Yes

O Yes

Intraparenchymal Hematoma—Parietal
32A

Parietal - Left?

O No

32B

Parietal - Left Depth

__ __ __ (mm)

32C

Parietal - Left Width

__ __ __ (mm)

32D

Parietal - Right?

O No

32E

Parietal - Right Depth

__ __ __ (mm)

32F

Parietal - Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina
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O (3) ≥ 1 mm thick

O Yes

O Yes

O (3) ≥ 1 mm thick

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
Intraparenchymal Hematoma—Occipital
33A

Occipital - Left?

O No

O Yes

33B

Occipital - Left Depth

__ __ __ (mm)

33C

Occipital - Left Width

__ __ __ (mm)

33D

Occipital - Right?

O No

33E

Occipital - Right Depth

__ __ __ (mm)

33F

Occipital - Right Width

__ __ __ (mm)

O Yes

Protect version 3 27Jan2012

Intraparenchymal Hematoma—Basal ganglia
34A

Basal ganglia- Left?

O No

O Yes

34B

Basal ganglia- Left Depth

__ __ __ (mm)

34C

Basal ganglia- Left Width

__ __ __ (mm)

34D

Basal ganglia- Right?

O No

34E

Basal ganglia- Right Depth

__ __ __ (mm)

34F

Basal ganglia- Right Width

__ __ __ (mm)

O Yes

Intraparenchymal Hematoma—Posterior fossa
35A

Posterior fossa - Left?

O No

O Yes

35B

Posterior fossa - Left Depth

__ __ __ (mm)

35C

Posterior fossa - Left Width

__ __ __ (mm)

35D

Posterior fossa - Right?

O No

35E

Posterior fossa - Right Depth

__ __ __ (mm)

35F

Posterior fossa - Right Width

__ __ __ (mm)

O Yes

Intraparenchymal Hematoma—Midbrain/pons
36

Midbrain/pons

O No

O Yes, 0-5 mm

37

Evidence of surgical evacuation?

O No

O Yes

38

Were there any brain contusion findings?
If no, skip to question 45.

O No

O Yes
O Yes

Brain Contusion—Frontal
39A

Frontal - Left?

O No

39B

Frontal - Left Depth

__ __ __ (mm)

39C

Frontal - Left Width

__ __ __ (mm)

39D

Frontal - Right?

O No

39E

Frontal - Right Depth

__ __ __ (mm)

39F

Frontal - Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

42

O Yes

O Yes, >5 mm

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Form 03: Radiology Assessment– Central Reader (version 3)
Brain Contusion—Temporal
40A

Temporal - Left?

O No

O Yes

40B

Temporal - Left Depth

__ __ __ (mm)

40C

Temporal - Left Width

__ __ __ (mm)

40D

Temporal - Right?

O No

40E

Temporal - Right Depth

__ __ __ (mm)

40F

Temporal - Right Width

__ __ __ (mm)

O Yes
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Brain Contusion—Parietal
41A

Parietal - Left?

O No

O Yes

41B

Parietal - Left Depth

__ __ __ (mm)

41C

Parietal - Left Width

__ __ __ (mm)

41D

Parietal - Right?

O No

41E

Parietal - Right Depth

__ __ __ (mm)

41F

Parietal - Right Width

__ __ __ (mm)

O Yes

Brain Contusion—Occipital
42A

Occipital - Left?

O No

O Yes

42B

Occipital - Left Depth

__ __ __ (mm)

42C

Occipital - Left Width

__ __ __ (mm)

42D

Occipital - Right?

O No

42E

Occipital - Right Depth

__ __ __ (mm)

42F

Occipital - Right Width

__ __ __ (mm)

O Yes

Brain Contusion—Basal ganglia
43A

Basal ganglia- Left?

O No

43B

Basal ganglia- Left Depth

__ __ __ (mm)

43C

Basal ganglia- Left Width

__ __ __ (mm)

43D

Basal ganglia- Right?

O No

43E

Basal ganglia- Right Depth

__ __ __ (mm)

43F

Basal ganglia- Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

43

O Yes

O Yes

Scan
received?
Data Collected?

O No

O Yes

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Form 03: Radiology Assessment– Central Reader (version 3)
Brain Contusion—Posterior fossa
44A

Posterior fossa - Left?

O No

44B

Posterior fossa - Left Depth

__ __ __ (mm)

44C

Posterior fossa - Left Width

__ __ __ (mm)

44D

Posterior fossa - Right?

O No

44E

Posterior fossa - Right Depth

__ __ __ (mm)

44F

Posterior fossa - Right Width

__ __ __ (mm)

Were there any DAI findings?
If no, skip to question 51.

O No

O Yes
O Yes

45

O Yes

O Yes
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DAI—Frontal
46A

Frontal - Left?

O No

46B

Frontal - Left Depth

__ __ __ (mm)

46C

Frontal - Left Width

__ __ __ (mm)

46D

Frontal - Right?

O No

46E

Frontal - Right Depth

__ __ __ (mm)

46F

Frontal - Right Width

__ __ __ (mm)

O Yes

DAI—Parietal
47A

Parietal - Left?

O No

O Yes

47B

Parietal - Left Depth

__ __ __ (mm)

47C

Parietal - Left Width

__ __ __ (mm)

47D

Parietal - Right?

O No

47E

Parietal - Right Depth

__ __ __ (mm)

47F

Parietal - Right Width

__ __ __ (mm)

O Yes

DAI—Basal ganglia
48A

Basal ganglia- Left?

O No

48B

Basal ganglia- Left Depth

__ __ __ (mm)

48C

Basal ganglia- Left Width

__ __ __ (mm)

48D

Basal ganglia- Right?

O No

48E

Basal ganglia- Right Depth

__ __ __ (mm)

48F

Basal ganglia- Right Width

__ __ __ (mm)

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

44

O Yes

O Yes

Scan
received?
Data Collected?

O No

O Yes

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

Form 03: Radiology Assessment– Central Reader (version 3)
DAI—Brainstem
49A

Brainstem - Present?

O No

O

49B

Brainstem - Depth

__ __ __ (mm)

49C

Brainstem - Width

__ __ __ (mm)

Yes

DAI—Corpus Callosum
50A

Corpus Callosum - Present?

O No

O

50B

Corpus Callosum - Depth

__ __ __ (mm)

50C

Corpus Callosum - Width

__ __ __ (mm)

Yes
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DAI—Centrum Semiovale
81A

Centrum Semiovale - Left?

O No

O

Yes

81B

Centrum Semiovale - Left Severity

O

O

Moderate

81C

Centrum Semiovale - Right?

O No

O

Yes

81D

Centrum Semiovale - Right Severity

O

O

Moderate

Were there any generalized edema findings?
If no, skip to question 53

O No

O

Yes

51

Mild

Mild

O

Severe

O

Severe

O

Severe

O

Severe

O

Severe

O

Severe

O

Severe

O

Severe

Generalized Edema - Hemisphere
52A

Hemisphere - Left?

O No

O

Yes

52B

Hemisphere - Left Severity

O

O

Moderate

52C

Hemisphere - Right?

O No

O

Yes

52D

Hemisphere - Right Severity

O

O

Moderate

Were there any focal swelling findings?
If no, skip to question 59.

O No

O

Yes

53

Mild

Mild

Focal Swelling - Frontal
54A

Frontal - Left?

O No

O

Yes

54B

Frontal - Left Severity

O

O

Moderate

54C

Frontal - Right?

O No

O

Yes

54D

Frontal - Right Severity

O

O

Moderate

Mild

Mild

Focal Swelling - Temporal
55A

Temporal - Left?

O No

O

Yes

55B

Temporal - Left Severity

O

O

Moderate

55C

Temporal - Right?

O No

O

Yes

55D

Temporal - Right Severity

O

O

Moderate

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

45

Mild

Mild

O Yes

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Scan
received?
Data Collected?

O No

O Yes

Form 03: Radiology Assessment– Central Reader (version 3)
Focal Swelling—Parietal
56A

Parietal - Left?

O No

O Yes

56B

Parietal - Left Severity

O Mild O Moderate O Severe

56C

Parietal - Right?

O No

56D

Parietal - Right Severity

O Mild O Moderate O Severe

O Yes
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Focal Swelling—Occipital
57A

Occipital - Left?

O No

O Yes

57B

Occipital - Left Severity

O Mild O Moderate O Severe

57C

Occipital - Right?

O No

57D

Occipital - Right Severity

O Mild O Moderate O Severe

O Yes

Focal Swelling—Basal ganglia
58A

Basal ganglia - Left?

O No

58B

Basal ganglia - Left Severity

O Mild O Moderate O Severe

58C

Basal ganglia - Right?

O No

58D

Basal ganglia - Right Severity

O Mild O Moderate O Severe

59

Were there any radiological signs of increased
ICP? If no, skip to question 71.

O No

O Yes

60

Sulcal obliteration

O Left

O Right

O Both

O None

61

Lateral ventricle compression

O Left

O Right

O Both

O None

62

Compression or obliteration of third ventricle and of basal cisterns

O No

O Yes

63

Midline shift

O To the Left

O To the Right

O None

64

If ‘midline shift, specify size

O 0-5mm

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

46

O Yes

O Yes

O > 5mm

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment

Form 03: Radiology Assessment– Central Reader (version 3)
65

Transtentorial herniation present?

O No

O Yes

66

Uncal herniation present?

O No

O Yes

67

Tonsillar herniation present?

O No

O Yes

68

Upward herniation present?

O No

O Yes

69

Other radiologic sign of increased ICP present?

O No

O Yes

70

If ’other radiologic sign of increased ICP’ specify:

71

Were there additional intracranial findings?
If no, skip to question 75.

O No

O Yes

Pseudoaneurysm - Present?

O No

O Yes

Pseudoaneurysm - If Yes, check all that apply

□ Right ICA
□ Right VA
□ Left ICA
□ Left VA

Additional Intracranial Findings - Pseudoaneurysm
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72A

72B

Additional Intracranial Findings - Dissection
73A

73B

Dissection - Present?

O No

O Yes

Dissection - If Yes, check all that apply

□ Right ICA
□ Right VA
□ Left ICA
□ Left VA

Additional Intracranial Findings - Infarction
74A

74B

Infarction - Present?

O No

Infarction - If Yes, check all that apply

□ Right ICA
□ Right VA
□ Left ICA
□ Left VA

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

47

O Yes

Scan
received?
Data Collected?

O No

O Yes

ProTECT

Visit:

___ ___ - ___ ___

___ ___ ___ ___

Hub - Spoke Code

Subject ID

___ ___ - ___ ___ ___ - ___ ___ ___ ___
(dd-mmm-yyyy)
Date of assessment
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Form 03: Radiology Assessment– Central Reader (version 3)

75A

Was there a skull fracture - Left?

O No

O Yes

75B

Was there a skull fracture - Right?

O No

O Yes

76

Depressed skull fracture

O No

O Yes

77

If [depressed skull fracture], is depression greater than the thickness of the skull?

O No

O Yes

78

Basilar skull fracture

O No

O Yes

79

Other skull fracture

O No

O Yes

80

If [other skull fracture], specify:

General Comments:

Name of person who collected this data (not for data entry):
Data Coordination Unit
Medical University of South Carolina

48

Scan
received?
Data Collected?

O No

O Yes

ProTECT III

Appendix 1
Protocol Summary - ProTECT™ III

TITLE OF THE TRIAL
Progesterone for the Treatment of Traumatic Brain Injury
TRIAL OBJECTIVES
Primary Objective
Determine the efficacy of administering intravenous (IV) progesterone (initiated within 4 hours of injury and
administered for 72 hours, followed by an additional 24 hour taper) versus placebo for treating victims of
moderate to severe acute TBI (Glasgow coma scale score 12-4).
Primary Hypothesis
Progesterone will increase the proportion of patients with a favorable outcome by a 10% (absolute) difference,
determined by the Glasgow Outcome Scale-Extended (GOSE) score at 6 months post injury when compared
to placebo. Our primary outcome analysis of the GOSE will use a stratified dichotomy methodology for
assessing improvement. This approach dichotomizes GOSE scores as “favorable” versus “not favorable”,
based on the brain injury severity score measured at randomization (best pre-randomization GCS or iGCS).
Patients with the most severe injury (iGCS 4-5) will have a favorable outcome if the GOSE is good to severe;
patients with an intermediate severe injury (iGCS 6-8) will have a favorable outcome if the GOSE is good to
moderate; and patients with a moderate injury (iGCS 9-12) will have a favorable outcome if the GOSE is good
recovery. A maximum of 1140 patients will be randomized, adjusting for age, gender, injury severity and
clinical site.
Secondary Endpoints
Examine the efficacy of IV progesterone vs. placebo for treating patients with moderate to severe acute TBI on
additional 6 month outcomes: Mortality, Disability Rating Scale (DRS), cognitive, neurological and functional
outcomes using a select battery of tests, and rates of adverse and serious adverse events.
Ancillary Study – BIO-ProTECT
The primary aim of this ancillary study is to determine whether elevated levels of serum biomarkers (including
S100B, GFAP, UCH-L1, SBDP150), measured within 4 hours of TBI or at 24 and 48 hours after randomization,
independently predict clinical outcome as measured by the Glasgow Outcome Scale Extended (GOS-E) at 6
months. The secondary aim is to determine, in progesterone treated subjects, if there a correlation between
steady state serum progesterone levels and serum levels of S100B, GFAP, UCH-L1, SBDP150 at 24 and 48
hours after randomization, and whether progesterone levels predict those subjects with a favorable clinical
response to the experimental treatment as determined by the primary outcome of the study.
METHODOLOGY
A double blind, randomized, placebo-controlled, multicenter clinical trial.
INFUSION PERIOD
Following a one hour loading dose, the study infusion (progesterone or placebo) will be administered as a
continuous intravenous infusion for 71 hours, and then tapered over three additional 8-hour decrements to
zero, for a total treatment duration of 96 hours.
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NUMBER OF SUBJECTS (planned)
The total sample size is 1140 subjects, calculated for a 1:1 randomization scheme with 85% power (feasible in
terms of number needed to enroll, and well within the accepted margins for error) to detect a 10% absolute
difference in outcomes between treatment groups at the two-sided α of 0.05. With these assumptions, we will
need 462 subjects per group (expected favorable outcome is 50% in those receiving placebo and 60% in those
given treatment) after accounting for 3 analyses (2 interim after approximately 33% and 67% of enrollment and
1 final) and using O’Brien Fleming boundaries. Assuming a conservative non-adherence rate of 10% (due to
withdrawal of consent during infusion and loss to follow-up), we will need a maximum of 1140 subjects to
ensure sufficient power to achieve our study goals.
NUMBER OF SITES (planned)
The ProTECT™ III Clinical Trial will partner with The Neurological Emergencies Treatment Trials (NETT)
network. The NETT is comprised of 17 Hubs, each consisting of several hospital complexes (Spokes).
INVESTIGATIONAL PRODUCT (dose, mode of administration)
Our current dose is 0.714 mg/kg bolus for 1 hour, followed by 0.5 mg/kg/hr for 71 hours, followed by a q 8 hour
decrement taper (3 changes) to zero.
TRIAL DURATION PER SUBJECT
From trial entry until 6 months post injury.
MAIN OUTCOMES
Primary Outcome
Our Primary Outcome will be GOSE 6 months post-injury. GOSE is the primary measure of functional outcome
and incorporates mortality in the primary outcome. A positive trial means that the treatment improves the
proportion of patients having a “favorable” outcome by 10% absolute value. Favorable outcome is defined as
described in the following table.
If the patient’s iGCS is:
4-5
6-8
9-12

If the iMotor Score is:
2-3
4-5

Then the favorable outcome is:
6 mo GOSE = severe, moderate, or good
6 mo GOSE = moderate or good
6 mo GOSE = good recovery

Secondary Outcomes
Secondary outcomes of interest include the effects of progesterone vs. placebo in patients with moderate to
severe TBI on 6 month mortality, Disability Rating Scale score, cognitive and neurological function outcomes
and the rates of adverse and serious adverse events.
SAFETY MONITORING
Adverse events will be defined and severity graded according to the Common Terminology Criteria for Adverse
Events (CTCAE). AEs will be submitted through the WebDCUTM and coded using MedDRA. Guidelines for
report content and structure will be provided. All adverse events will be recorded for the first 7 days after
enrollment (4 days of drug infusion and 3 days post infusion). Based on the reported potential risks of
progesterone administration, several important risks were identified that could be associated with progesterone
(serious thromboembolic events such as thrombotic myocardial infarction, pulmonary embolism, deep vein
thrombosis, ischemic stroke; allergic reactions; marked liver function abnormalities; serious infections such as
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pneumonia, sepsis, meningitis) and have labeled them as “potentially associate adverse events” (PAAE).
Study personnel will evaluate subjects while in the hospital and at each telephone communication and followup for the presence of PAAEs or SAEs using a pre-constructed checklist. Sites will record and report PAAEs
and SAEs within 24 hours of discovery throughout the course of the subject’s participation (6 months).
We have employed two independent medical safety monitors (IMSM) with extensive expertise to review the
PAAEs and SAEs, and provide causality judgments. Together they will provide daily coverage for the
ProTECT™ III trial. The IMSM will make a determination of causality and expectedness based on
predetermined criteria. IMSM reports that are serious, unexpected, and study drug related (possibly, probably,
or definitely) will immediately be sent to the ProTECT™ III PI and Project Manager, who will submit a
MedWatch 3500A to the FDA. Reports will be routed to each institution’s IRB (via the CCC and institutional
PIs). Other measures to safeguard the welfare of study subjects include a formal review of all deaths by the
trauma outcomes review committee at each site and a regularly scheduled comprehensive review of all safety
data and AB physiological measurements by an independent NIH appointed Data and Safety Monitoring Board
(DSMB).
STATISTICAL METHODS TO ANALYZE THE PRIMARY OUTCOME
Outcome differences will be analyzed on the basis of intention-to-treat. To assess efficacy, the treatment
groups will be compared with respect to the proportion of subjects with favorable outcome 6 months post
randomization. The primary efficacy hypothesis is tested via generalized linear model relating the probability of
a favorable outcome to the treatment, adjusting for three covariates - injury severity, gender, and age.
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(74.3%)
(15.6%)
(10.1%)

(73.7%)
(26.3%)

-‐1.1%

-‐0.4%
2.6%
-‐2.2%

-‐1.7%
+1.7%

+CT

557
199

(14.3%)

-‐tSAH

562
118
76

+tSAH

108

32

132
83
52
53
23
34

(35.0%)
(22.0%)
(13.8%)
(14.1%)
(6.1%)
(9.0%)

262
150
106
123
43
72

(34.7%)
(19.8%)
(14.0%)
(16.3%)
(5.7%)
(9.5%)

-‐0.7%
-‐4.3%
0.5%
4.4%
-‐0.8%
1.0%

1.6
+2

(34.3%)
(17.7%)
(14.2%)
(18.5%)
(5.3%)
(10.0%)

0
-‐1.9%
0.8%

130
67
54
70
20
38

39.69 (±17.9)
36
17-‐94

0.2%

(74.5%)
(25.5%)

38.9 (±17.4)
35
17-‐93

377

(74.5%)
(14.3%)
(11.1%)
-‐12.4%
-‐7.3%
-‐1.5%
-‐8.8%
-‐0.8%
+7.9%

Δ
379 (50.1%)

281
96

(14.9%)
72
36
16

(41.4%)
(20.7%)
(9.2%)
(29.9%)
(4.0%)
(10.3%)

756
40.5 (±18.3)
37
17-‐94

281
54
42

7
18

total

-‐4.6%

276 (72.8%)
103 (27.2%)

56

43
22
9

(47.3%)
(24.2%)
(9.9%)
(34.1%)
(4.4%)
(6.6%)

(49.9%)

7.1
+7

281 (74.1%)
64 (16.9%)
34 (9.0%)

4
6

placebo

-‐2.4%
+2.4%

52 (13.7%)

PROG

-‐8.1%
-‐13.2%
-‐5.1%

Δ

(73.6%)
(26.4%)

-‐7.8%

174

128
46
(74.1%)
(18.4%)
(7.5%)

total

129

(16.1%)

placebo

(74.7%)
(25.3%)

13

91 (52.30%)

68
23

28

PROG

71

(78.0%)
(12.1%)
(9.9%)

83 (47.70%)

11
(19.8%)

+1.8%

placebo

9

Δ

286 (49.1%)

60 (72.3%)
23 (27.7%)

18

582

PROG

-‐

58 (69.9%)
21 (25.3%)
4 (4.8%)

total

296 (50.9%)

-‐1.5%
+1.5%

10 (12.0%)

N=
41.0 (±18.2)
39
17-‐93

+1.9%
-‐0.5%
-‐1.4%
29 (34.9%)
14 (16.9%)
7 (8.4%)
21 (25.3%)
3 (3.6%)
12 (14.5%)

(1.1%)
(1.7%)
(4.1%)

0:00
0:01
0:05

8
13
31

(±0:27)
(±0:34)
(±0:51)

(1.1%)
(2.7%)
(3.7%)

0:52
1:24
3:40

4
10
14

(±0:26)
(±0:31)
(±0:44)

(1.1%)
(0.8%)
(4.5%)

0:52
1:24
3:37

4
3
17

0:52 (±0:28)
1:25 (±0:36)
3:42 (±0:58)

-‐

429 (73.6%)
153 (26.3%)

+1.0%
+3.0%
-‐3.4%
+0.9%
+1.5%
-‐0.9%
-‐1.1%

52

(32.7%)
(19.6%)
(15.5%)
(16.8%)
(6.2%)
(9.3%)

-‐0:03
0:05
0:01

31

190
114
90
98
36
54

(±0:28)
(±0:33)
(±0:37)

0.0%
0.1%
0.2%

0:53
1:26
3:36

0
2
4

(0.0%)
(1.1%)
(2.3%)

(±0:25)
(±0:28)
(±0:30)

0
1
2

(0.0%)
(1.1%)
(2.2%)

0:54
1:24
3:36

0 (0.0%)
1 (1.2%)
2 (2.4%)

0:51 (±0:30)
1:29 (±0:37)
3:37 (±0:43)

0.0%
-‐2.5%
0.9%

0:01
-‐0:01
0:07

8 (1.4%)
11 (1.9%)
27 (4.6%)

0:52 (±0:26)
1:24 (±0:34)
3:41 (±0:55)

-‐

41.1 (±18.0)
39
17-‐93

433 (74.3%)
86 (14.7%)
63 (10.8%)

35.4 (±16.6)
30
17-‐94

213 (74.5%)
73 (25.5%)

80 (13.7%)

32.0 (±13.3)
28
18-‐67

40.86 (±18.1)
38
18-‐88

210 (73.4%)
43 (15.0%)
33 (11.5%)

39.1 (±19.0)
35
17-‐94

216 (73.0%)
80 (27.0%)

38 (13.2%)

-‐0.2
-‐1

223 (75.3%)
43 (14.5%)
30 (10.1%)

Demographics
Age-‐mean
	
  	
  	
  -‐median
	
  	
  	
  -‐range
Sex-‐male
	
  	
  	
  -‐female

42 (14.2%)
(31.1%)
(21.3%)
(15.0%)
(16.1%)
(6.6%)
(9.8%)

4 (1.4%)
9 (3.1%)
12 (4.2%)

0:51 (±0:26)
1:24 (±0:32)
3:37 (±0:48)

89
61
43
46
19
28

Race-‐white
	
  	
  	
  -‐black
	
  	
  	
  -‐other
Ethnicity-‐hispanic
101
53
47
52
17
26

(1.4%)
(0.7%)
(5.1%)

(34.1%)
(17.9%)
(15.9%)
(17.6%)
(5.7%)
(8.7%)

Mechanism-‐MVC
	
  	
  	
  -‐MCC/ATV
	
  	
  	
  -‐person	
  hit	
  by	
  auto
	
  	
  	
  -‐falls
	
  	
  	
  -‐bicycle	
  crash
	
  	
  	
  -‐other
0:52 (±0:27)
1:23 (±0:36)
3:44 (±1:01)

4
2
15

Time-‐injury	
  to	
  ED	
  arrival	
  mean
	
  	
  	
  -‐injury	
  to	
  CT	
  scan	
  mean
	
  	
  	
  -‐injury	
  to	
  study	
  tx	
  mean
Prognosticators/covariates
Significant	
  hypoxia
Significant	
  hypotension
No	
  pupillary	
  response

52

Classifications
GCS-‐mean
AIS	
  head-‐mean
Rotterdam	
  score-‐mean
ISS-‐mean
ISS-‐median

Epidural	
  hematoma
Subdural	
  hematoma
Intraparenchymal	
  
	
  	
  	
  hematoma
Brain	
  contusion
Diffuse	
  axonal	
  injury
Skull	
  fracture
Increased	
  ICP
Generalized	
  edema
Focal	
  swelling

n	
  =	
  83

PROG

8.3
3.7
2.2
23.1

(13.2%)
(42.9%)

(±2.5)
(±1.1)
(±0.7)
(±9.8)
24

n	
  =	
  91

placebo

0.4%

1.3%
12.6%

0
-‐1
0
+0.2
-‐2.5

Δ	
  

8.3 (±2.3)
3.6 (±1.1)
2.2 (±0.8)
23.3 (±11.0)
21.5

12
39

(4.4%)

5.5%
-‐4.2%
6.0%
0.9%
-‐0.3%
3.7%

-‐tSAH

+10

(14.5%)
(55.4%)

4

(31.9%)
(31.9%)
(49.5%)
(22.0%)
(9.9%)
(1.1%)

+tSAH

0
0
0
+0.2
-‐1
12
46

(4.8%)

29
29
45
20
9
1

Δ	
  

(±2.3)
(±0.9)
(±0.9)
(±10.4)
27
4.9%
-‐2.0%

4

(37.3%)
(27.7%)
(55.4%)
(22.9%)
(9.6%)
(4.8%)

placebo

45 (15.7%)
167 (58.4%)

-‐2.3%

31
23
46
19
8
4

PROG

(±2.4)
(±0.9)
(±0.9)
(±11.2)
26

(8.4%)

3.1%
-‐3.5%
-‐1.9%
-‐0.2%
-‐1.7%
1.4%

-‐8

7.7
4.0
3.3
27.0

(20.6%)
(56.4%)
24

(47.2%)
(33.9%)
(56.3%)
(36.7%)
(29.4%)
(7.3%)

n	
  =	
  286

61
167
(6.1%)
135
97
161
105
84
21

n	
  =	
  296

18
(50.3%)
(30.4%)
(54.4%)
(36.5%)
(27.7%)
(8.8%)

7.7
4.0
3.3
26.8

149
90
161
108
82
26

53

Concomitant	
  injuries
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+tSAH

Δ

+CT

0.2%

-‐tSAH

756

-‐0.1

total

(±2.4)

+2.8%
+0.5%
-‐2.9%
-‐2.3%
+2.4%
+2.5%
-‐0.4%
-‐2.6%

377

4.5

(20.5%)
(1.7%)
(15.4%)
(8.8%)
(8.4%)
(20.9%)
(15.6%)
(8.7%)

placebo

(±2.3)

149
12
112
64
61
152
113
63

379
4.6

(19.1%)
(1.4%)
(16.9%)
(10.0%)
(7.2%)
(19.7%)
(15.8%)
(10.0%)

PROG

(±2.4)

69
5
61
36
26
71
57
36

Δ

4.5

(21.9%)
(1.9%)
(14.0%)
(7.7%)
(9.6%)
(22.2%)
(15.3%)
(7.4%)

-‐8
-‐0.1

80
7
51
28
35
81
56
27

174
(±2.3)

+2.3%
-‐1.1%
+0.5%
-‐3.0%
+0.8%
+1.2%
-‐1.5%
+1.0%

total

4.2
(12.6%)
(0.6%)
(6.0%)
(6.6%)
(9.6%)
(28.1%)
(24.6%)
(12.0%)

91
(±2.4)
21
1
10
11
16
47
41
20

placebo

4.3
(11.5%)
(1.1%)
(5.7%)
(8.0%)
(9.2%)
(27.6%)
(25.3%)
(11.5%)

83
(±2.3)
10
1
5
7
8
24
22
10

PROG

4.2
(13.8%)
(0.0%)
(6.3%)
(5.0%)
(10.0%)
(28.8%)
(23.8%)
(12.5%)

+10
-‐0.1
11
0
5
4
8
23
19
10

Δ

(±2.3)
+2.7%
+1.0%
-‐4.3%
-‐2.2%
+2.9%
+3.2%
+0.2%
-‐3.5%

582
4.2
(22.9%)
(2.0%)
(18.2%)
(9.5%)
(8.1%)
(18.8%)
(12.9%)
(7.7%)

total

(±2.4)
128
11
102
53
45
105
72
43

286
4.3
(21.5%)
(1.5%)
(20.4%)
(10.6%)
(6.6%)
(17.2%)
(12.8%)
(9.5%)

placebo

4.2 (±2.3)
59
4
56
29
18
47
35
26

-‐0.6%

296

(24.2%)
(2.5%)
(16.1%)
(8.4%)
(9.5%)
(20.4%)
(13.0%)
(6.0%)

(4.0%)

PROG
Outcomes
GOSE-‐mean
69
7
46
24
27
58
37
17

30

N=

GOSE	
  1	
  (Mortality)
GOSE	
  2
GOSE	
  3
GOSE	
  4
GOSE	
  5
GOSE	
  6
GOSE	
  7
GOSE	
  8

(4.2%)

+1.9%
-‐1.9%

16

(53.6%)
(46.4%)

-‐3.1%

(3.7%)

389
337

(30.6%)

14

190 (52.6%)
171 (47.4%)

45

-‐0.8%

(54.5%)
(45.5%)

20 (29.0%)

(4.0%)

199
166

(32.1%)

7

+1.4%
-‐1.4%

25

(4.4%)

(81.0%)
(28.1%)

-‐3.6%

4

124
43

(38.1%)

(3.6%)

64 (73.6%)
23 (26.4%)

8

3
(75.0%)
(25.0%)

4 (40.0%)

-‐0.5%
60
20
(36.4%)

(4.0%)
+2.8%
-‐2.8%
4

23
265 (47.4%)
294 (52.6%)
+3.3%

(4.2%)

126 (46.0%)
148 (54.0%)
37 (28.9%)

12

139 (48.8%)
146 (51.2%)
16 (27.1%)

11 (3.7%)

21 (30.4%)

Missing	
  outcome
Fixed	
  dichotomy	
  favorable
Fixed	
  dichotomy	
  unfavorable

Death	
  of	
  non-‐neurological	
  etiology
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